# Eval result: 14/14 — PASS

| Dimension | Score | Evidence |
|---|---|---|
| A_design_space | 2 | Single exon-55 skip rejected by arithmetic ("190 bp, frame remainder 1"); both dual skips enumerated and compared (54-55 −115 aa vs 55-56 −121 aa) against 52-55, 48-55, 50-55, 45-55 in a computed bp/aa table; 45-55 explicitly demoted as "unnecessary... for a single exon-55 PTC". |
| B_product_reasoning | 2 | Per-product domain analysis (108-aa "hybrid repeat" at 53|56 vs "6-aa R22 stub" for 55-56), nNOS retention, human anchors (asymptomatic del48-55 male CK 198; 75/83 del45-55 BMD), Dmd Δ52-55 mouse rescue plus 52-week exercise decrement, and honest "No person with a deletion of exons 54 and 55 has been described". |
| C_delivery | 2 | "Separate payload from delivery"; naked PMO for discovery only, TfR1 Fab/mAb for the clinical asset; platform table compares dose (5 mg/kg Q6W, 20 mg/kg Q4W vs weekly 30-80 mg/kg), cardiac access, hypomagnesemia/eGFR PPMO tox, satellite cells, and access/IP; notes naked PMO "leaves the heart essentially untreated". |
| D_currentness | 2 | DYNE-255 exon-55 TfR1-Fab at IND-enabling stage (with the correct caveat that it targets single-skip-amenable deletions, not this PTC), del-zota/Avidity–Novartis EXPLORE44, DYNE-251 BLA, Wave WVE-N531, BMN 351, Entrada, PepGen discontinuation, Ionis/Bicycle TfR1 ligand, PBGENE-DMD base editing. |
| E_program_selection | 2 | "LEAD — Remove DMD exons 54 and 55 together... Published work shows one oligonucleotide against exon 54 can pull exon 55 out with it" + TfR1 conjugate for the clinical asset; backup 55+56 with stated switch condition; 52-55 cocktail as lower priority; verdict "TEST FIRST" with the coupling ratio named as the gating unknown. |
| F_experiment | 2 | Patient myotubes carrying the exon-55 PTC, ~20 tiled exon-54 PMOs plus exon-55 walk and paired cocktail, long-range transcript sequencing + WB/MS + IF, quantitative success (in-frame 53|56 dominant, ≥20% of transcript, cryptic <2%) and kill criteria that explicitly retire the one-oligo lead and then the whole del54-55 product. |
| G_concision | 2 | 1021 words, bulleted, scannable headings (Recommendation / Delivery / Backup / Critical risk / First experiment / Key precedents); no literature-review drift — the review material is quarantined in the appendix. Minor overlap between "Recommendation" and "Why this design". |

## Unacceptable failures
- [ok] jumps directly to exon 45-55 skipping — 45-55 placed in WATCH; "needs 5-6 oligos — all unnecessary for a single exon-55 PTC".
- [ok] misses both 54+55 and 55+56 — Both found, costed in amino acids, and compared head-to-head on junction structure and oligo count.
- [ok] does not investigate coordinated skipping — Found and quoted the exon-54→54+55 co-skipping report plus independent restatement; flagged ratio as unverified.
- [ok] treats exon-44 dystrophin levels as transferable efficacy expectations — Dedicated "Non-transferable benchmarks" section; "honest prior is a fraction of a single-skip number".
- [ok] treats naked PMO as state-of-the-art muscle delivery without justification — Naked PMO used only as a discovery-stage tool and chemistry/safety precedent; TfR1 conjugate is the clinical asset.
- [ok] misses current TfR1-directed muscle programs — Dyne FORCE, Avidity AOC/Novartis, and preclinical Ionis/Bicycle TfR1 bicyclic peptide all captured.
- [ok] misses relevant exon-55 competitive activity — DYNE-255 identified and correctly characterised as an exon-55-directed TfR1-Fab PMO at IND-enabling stage.
- [ok] recommends a splice product without evaluating protein functionality — Domain, spectrin-repeat phasing, nNOS, Becker genotype and mouse rescue evidence for every candidate.
- [ok] produces a long literature review instead of a program recommendation — Main answer is a 1021-word decision document; evidence is appendixed.

## Required discoveries missed
- Required discovery 6 (partial): the agent argues exon-44 numbers are non-transferable on grounds of single- vs dual-skip yield, delivery and validated Becker genotype, but never states that exon 44 has unusual endogenous/natural skipping behaviour — the specific mechanistic reason named in the fixture. The non-transferability warning also sits only in the appendix, not the main answer.
- Minor: the first experiment contains no exon-56 arm, so the 55+56 backup is reached only by kill-criterion inference rather than being tested in parallel.

Strong pass, 14/14. The agent rejected the single exon-55 skip on frame arithmetic, enumerated both dual skips with protein-level comparison, independently surfaced the exon-54→54+55 coordinated-skipping literature and correctly treated it as unverified, separated payload from TfR1-conjugate delivery, and found DYNE-255. No unacceptable failure triggered. Gaps are narrow: exon-44's endogenous-skipping idiosyncrasy is never named, the non-transferability warning is appendix-only, and the first experiment omits an exon-56 arm.
